Trial Profile
Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Paclitaxel (Primary)
- Indications Head and neck cancer; Mouth neoplasm; Squamous cell cancer
- Focus Therapeutic Use
- 05 Feb 2024 Planned End Date changed from 2 Dec 2026 to 2 Feb 2027.
- 03 Jul 2023 Primary endpoint (Pathologic complete response rate (pCRR) after induction chemotherapy with carboplatin, nab-paclitaxel, and durvalumab in previously untreated stage III and IV SCCHN amenable to surgical resection) has not been met, as per results published in the Cancer.
- 03 Jul 2023 Results (Between December 2017 and November 2021) assessing the safety and efficacy of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma, published in the Cancer.